NEW YORK (GenomeWeb News) — Transgenomic today said that Italian molecular diagnostic shop Fiuotecnica will use its Wave technology to develop and market a genetic assay panel to predict the risk of cardiovascular disease and heart attacks.
Fiuotecnica will retain rights to market the panel in Italy and Transgenomic will obtain rights to market it in the rest of the world.
Financial terms of the agreement were not disclosed.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.